Skip to main content
Top
Published in: PharmacoEconomics 1/2005

01-12-2005 | Original Research Article

Modelling the treated course of schizophrenia: Development of a discrete event simulation model

Authors: Bart M. S. Heeg, Erik Buskens, Martin Knapp, Gerda van Aalst, Pieter J. T. Dries, Lieuwe de Haan, Ben A. van Hout

Published in: PharmacoEconomics | Special Issue 1/2005

Login to get access

Abstract

In schizophrenia, modelling techniques may be needed to estimate the long-term costs and effects of new interventions. However, it seems that a simple direct link between symptoms and costs does not exist. Decisions about whether a patient will be hospitalized or admitted to a different healthcare setting are based not only on symptoms but also on social and environmental factors. This paper describes the development of a model to assess the dependencies between a broad range of parameters in the treatment of schizophrenia. In particular, the model attempts to incorporate social and environmental factors into the decision-making process for the prescription of new drugs to patients. The model was used to analyse the potential benefits of improving compliance with medication by 20% in patients in the UK. A discrete event simulation (DES) model was developed, to describe a cohort of schizophrenia patients with multiple psychotic episodes. The model takes into account the patient’s sex, disease severity, potential risk of harm to self and society, and social and environmental factors. Other variables that change over time include the number of psychiatric consultations, the presence of psychotic episodes, symptoms, treatments, compliance, side-effects, the lack of ability to take care of him/herself, care setting and risk of harm. Outcomes are costs, psychotic episodes and symptoms. Univariate and multivariate sensitivity analyses were performed. Direct medical costs were considered (year of costing 2002), applying a 6.0% discount rate for costs and a 1.5% discount rate for outcome. The timeframe of the model is 5 years. When 50% of the decisions about the patient care setting are based on symptoms, a 20% increase in compliance was estimated to save £16 147 and to avoid 0.55 psychotic episodes per patient over 5 years. Sensitivity analysis showed that the costs savings associated with increased compliance are robust over a range of variations in parameters. DES offers a flexible structure for modelling a disease, taking into account how a patient’s history affects the course of the disease over time. This approach is particularly pertinent to schizophrenia, in which treatment decisions are complex. The model shows that better compliance increases the time between relapses, decreases the symptom score, and reduces the requirement for treatment in an intensive patient care setting, leading to cost savings. The extent of the cost savings depends on the relative importance of symptoms and of social and environmental factors in these decisions.
Literature
1.
go back to reference Schizophrenia Platform. Divided attention, shared care: from problem areas to quality in the care of patients with schizophrenia. The Netherlands: Schizophrenia Platform, May 2000 Schizophrenia Platform. Divided attention, shared care: from problem areas to quality in the care of patients with schizophrenia. The Netherlands: Schizophrenia Platform, May 2000
2.
go back to reference National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National clinical practice guideline number 1. London: NICE, 2003 National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. National clinical practice guideline number 1. London: NICE, 2003
3.
go back to reference Tran PV, Dellva M, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172: 499–505PubMedCrossRef Tran PV, Dellva M, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998; 172: 499–505PubMedCrossRef
4.
go back to reference Sartorius N, Fleischhacker W, Gjerris A, et al. The usefulness and use of second generation antipsychotic medications: review of evidence and recommendations by a task force of the World Psychiatric Association. Curr Opin Psychiatry 2002; 15 (Suppl. 1): 1–51 Sartorius N, Fleischhacker W, Gjerris A, et al. The usefulness and use of second generation antipsychotic medications: review of evidence and recommendations by a task force of the World Psychiatric Association. Curr Opin Psychiatry 2002; 15 (Suppl. 1): 1–51
5.
go back to reference Caro JJ. Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 2005; 23: 323–32PubMedCrossRef Caro JJ. Pharmacoeconomic analyses using discrete event simulation. PharmacoEconomics 2005; 23: 323–32PubMedCrossRef
6.
go back to reference Sadock BJ, Sadock VA. Kaplan & Sadock’s pocket handbook of clinical psychiatry, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins, 2001. Sadock BJ, Sadock VA. Kaplan & Sadock’s pocket handbook of clinical psychiatry, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins, 2001.
8.
go back to reference Csernansky JG, Mahmoud R, Brenner R. and the Risperidone-USA-79 Study GroupA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22PubMedCrossRef Csernansky JG, Mahmoud R, Brenner R. and the Risperidone-USA-79 Study GroupA comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22PubMedCrossRef
9.
go back to reference McIntyre R, Trakas K, Lin D, et al. Risk of adverse events associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia (CNOMSS). 51st Annual Canadian Psychiatric Association Meeting; 2001 Nov 15-19; Montreal, Canada McIntyre R, Trakas K, Lin D, et al. Risk of adverse events associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia (CNOMSS). 51st Annual Canadian Psychiatric Association Meeting; 2001 Nov 15-19; Montreal, Canada
10.
go back to reference Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63PubMedCrossRef Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–63PubMedCrossRef
11.
go back to reference Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 (Suppl. 16): 10–3PubMed Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 (Suppl. 16): 10–3PubMed
12.
go back to reference Health Care Insurance Board. Pharmacopoeia, the Netherlands 2002. Amstelveen: Health Care Insurance Board, November 2001. p. 84 Health Care Insurance Board. Pharmacopoeia, the Netherlands 2002. Amstelveen: Health Care Insurance Board, November 2001. p. 84
13.
go back to reference Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54: 253–64PubMedCrossRef Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002; 54: 253–64PubMedCrossRef
14.
go back to reference Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors — a United States perspective. J Clin Psychiatry 1984; 45: 36–42PubMed Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors — a United States perspective. J Clin Psychiatry 1984; 45: 36–42PubMed
15.
go back to reference Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239–45PubMed Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239–45PubMed
16.
go back to reference Taylor DM, Wright T, Libretto SE. and the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator GroupRisperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003; 64: 589–97PubMedCrossRef Taylor DM, Wright T, Libretto SE. and the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator GroupRisperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003; 64: 589–97PubMedCrossRef
17.
go back to reference Larsen TK, Moe LC, Vibe-Hansen L, et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000; 45: 1–9PubMedCrossRef Larsen TK, Moe LC, Vibe-Hansen L, et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000; 45: 1–9PubMedCrossRef
18.
go back to reference Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [Review]. BMJ 2000; 321: 1371–6PubMedCrossRef Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [Review]. BMJ 2000; 321: 1371–6PubMedCrossRef
20.
go back to reference Arango C, Calcedo Barba A, Gonzalez-Salvador C, et al. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999; 25: 493–503PubMedCrossRef Arango C, Calcedo Barba A, Gonzalez-Salvador C, et al. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999; 25: 493–503PubMedCrossRef
21.
go back to reference Cheung P, Schweitzer I, Crowley K, et al. Aggressive behaviour in schizophrenia: the role of psychopathology. Aust NZ J Psychiatry 1997; 31: 62–7CrossRef Cheung P, Schweitzer I, Crowley K, et al. Aggressive behaviour in schizophrenia: the role of psychopathology. Aust NZ J Psychiatry 1997; 31: 62–7CrossRef
22.
go back to reference Drug Tariff November 2002. London: Department of Health & National Assembly for Wales, 2002 Drug Tariff November 2002. London: Department of Health & National Assembly for Wales, 2002
24.
go back to reference National Institute for Clinical Excellence. Guidance for manufacturers and sponsors: technology appraisals process series No 5. London: National Institute for Clinical Excellence, 2001 National Institute for Clinical Excellence. Guidance for manufacturers and sponsors: technology appraisals process series No 5. London: National Institute for Clinical Excellence, 2001
25.
go back to reference Guest J, Cookson R. Cost of schizophrenia to UK Society. An incident-based cost-of-illness model for the first 5 years following diagnosis. PharmacoEconomics 1999; 15: 597–610PubMedCrossRef Guest J, Cookson R. Cost of schizophrenia to UK Society. An incident-based cost-of-illness model for the first 5 years following diagnosis. PharmacoEconomics 1999; 15: 597–610PubMedCrossRef
Metadata
Title
Modelling the treated course of schizophrenia: Development of a discrete event simulation model
Authors
Bart M. S. Heeg
Erik Buskens
Martin Knapp
Gerda van Aalst
Pieter J. T. Dries
Lieuwe de Haan
Ben A. van Hout
Publication date
01-12-2005
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue Special Issue 1/2005
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523001-00003

Other articles of this Special Issue 1/2005

PharmacoEconomics 1/2005 Go to the issue